Fortrea Holdings Inc FTRE

$20.56 -0.22 (-1.06%)

Valuation

Market cap
1,976,178,000
Revenue TTM
$2,723,400,000
Net income TTM
$-986,200,000
PE ratio
35.18
Forward PE
24.75
Profit margin
-36.21%
Debt to equity
2.01

Trading

Volume
2,245,300
Avg volume
1,525,712
Day's range
$20.24 – $21.11
Shares out
95,100,000
Stochastic %K
34%
Beta
1.93
Analysts
Sell
Price target
$21.50

Price

Company profile

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and...

Show more

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Industry
Biotechnology
Sector
Healthcare
Phone
877 495 0816
Website
https://www.fortrea.com
Address
8 Moore Drive, Durham, United States

Latest news

No headlines yet.